• 1
    Hutter A, Schwetye K, Bierhals A, McKinstry R. Brain neoplasms: epidemiology, diagnosis, and prospects for cost-effective imaging. Neuroimaging Clin N Am. 2003; 2: 237250.
  • 2
    Honig A, Rieger L, Sutterlin A, et al. Brain metastases in breast cancer—an in vitro study to evaluate new systemic chemotherapeutic options. Anticancer Res. 2005; 25: 15311537.
  • 3
    Kirsch DG, Loeffler JS. Brain metastases in patients with breast cancer: new horizons. Clin Breast Cancer. 2005; 6: 115124.
  • 4
    Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004; 22: 36083617.
  • 5
    Surma-aho O, Niemela M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology. 2001; 56: 12851290.
  • 6
    DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989; 39: 789796.
  • 7
    Fenner MH, Possinger K. Chemotherapy for breast cancer brain metastases. Onkologie. 2002; 25: 474479.
  • 8
    Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987996.
  • 9
    Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002; 20: 36443650.
  • 10
    Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2001; 53: 259265.
  • 11
    Martinez-Cedillo J, Alvarado A, Lara F, et al. Temozolomide (TMZ) in metastatic breast cancer (BC) to central nervous system (CNS). Proc Am Soc Clin Oncol. 2003; 22: 88. Abstract.
  • 12
    Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol. 2001; 12: 249254.
  • 13
    Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol. 2001; 24: 421424.
  • 14
    Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J. 2003; 5: 833834.
  • 15
    Zubrod C, Scheiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and thiophosphoamide. J Chron Dis. 1960; 11: 733.
  • 16
    Benedict RHB, Schretien D, Groninger L, et al. Hopkins verbal learning test-revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998; 12: 4355.
  • 17
    Benton AL, Hamsher KDS. Multilingual Aphasia Examination. 3rd edition. Iowa City, IA: AJA Association, 1989.
  • 18
    Wechsler D. Wechsler Adult Intelligence Scale III. 3rd ed. San Antonio, TX: Psychological Corporation, 1997.
  • 19
    Lezak MD. Neuropsychological Assessment. 3rd ed. New York: Oxford University Press, 1995.
  • 20
    Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil. 2002; 83: S10S17.
  • 21
    Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004; 22: 157165.
  • 22
    Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer. 1992; 69: 972980.
  • 23
    Trudeau ME, Eisenhauer E, Dent S, et al. Central nervous system (CNS) relapse following chemotherapy with docetaxel for metastatic breast cancer. Update of a study by the National Cancer Institute of Canada–Clinical Trials Group (NCIC-CTG). Proc Am Soc Clin Oncol. 1996; 15: 101. Abstract 68.
  • 24
    Siena S, Landonio G, Baietta E, et al. Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small lung cancer. Proc Am Soc Clin Oncol. 2003; 22: 102. Abstract.